Skip Navigation LinksHome > March 2014 - Volume 29 - Issue 2 > The advantage of using 3-week data to predict response to ar...
International Clinical Psychopharmacology:
doi: 10.1097/YIC.0000000000000005
Original Articles

The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis

Park, Jong-Ila; Cho, Dong-Hwanc; Hahn, Sang Wood; Jeong, Bumseoke; Kim, Jong-Hoonf; Kim, Sung-Wang; Koo, Min-Seongh; Lee, Seung Hwani; Lee, Seung Jaej; Lee, Yo Hank; Park, Jong-Ikl; Rho, Seung Hom; Chung, Young-Chula,b

Collapse Box

Abstract

We investigated the efficacy and safety of aripiprazole in first-episode psychosis and explored the association between early response and later response to this medication. This was a 6-week, open-label, multicenter trial. The study population consisted of 59 patients with a DSM-IV diagnosis of a schizophreniform disorder, schizoaffective disorder, schizophrenia, or psychotic disorder not otherwise specified. The primary outcome measures were the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity scale. To assess the safety, we measured the drug-related adverse events, weight, and lipid-related variables. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the response status at weeks 2 and 3 to predict the subsequent response at week 6. Among the 59 participants, 38 were able to complete the 6-week trial. Treatment with aripiprazole resulted in significant improvement in the PANSS and Clinical Global Impression scores over time. The response rate (defined as a ≥30% decrease in the PANSS total score from baseline to the last observation) was 69.1%. The most accurate prediction of later response in terms of negative predictive value and specificity was a reduction in the PANSS total score from baseline to week 3 of at least 20%. Aripiprazole had a modest side effect burden and was characterized by a safe profile with respect to weight and metabolic side effects. These results indicate that aripiprazole is effective and safe in the treatment of first-episode psychosis. The response at week 3, rather than week 2, predicted the later response more accurately.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.